Valuation: Virbac

Market Cap 2.89B 3.34B 2.7B 2.47B 4.65B 318B 4.73B 31.68B 12.43B 159B 12.54B 12.26B 531B P/E 2026 *
16.9x
P/E 2027 * 15.3x
Enterprise Value 3.02B 3.49B 2.82B 2.58B 4.86B 332B 4.93B 33.07B 12.98B 166B 13.09B 12.8B 554B EV / Sales 2026 *
1.95x
EV / Sales 2027 * 1.8x
Free-Float
49.03%
Yield 2026 *
0.5%
Yield 2027 * 0.59%
1 week+1.93%
Current month+1.93%
1 month+5.68%
3 months-6.01%
6 months-1.85%
Current year-3.23%
1 week 332
Extreme 332
348
1 month 314
Extreme 314
349.5
3 years 241
Extreme 241
394.5
5 years 216.5
Extreme 216.5
441.5
10 years 101.68
Extreme 101.682
441.5
Manager TitleAgeSince
Chief Executive Officer 46 31/08/2025
Chief Executive Officer 50 26/09/2024
Chief Operating Officer 64 31/12/2021
Director TitleAgeSince
Chairman 61 31/03/2006
Director/Board Member 68 27/07/2010
Director/Board Member 65 04/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
-2.91%+1.93%+5.52%+23.52% 3.34B
+1.27%-5.14%-50.92%-61.32% 30.02B
+0.88%-14.33%+28.86%+80.32% 11.05B
+1.54%+1.90%-15.05%+5.67% 3.86B
-3.19%-1.04%+1.52%+16.78% 3.34B
+0.79%+10.52%+63.20%+39.84% 2.24B
+0.71%+1.73%+10.88%+24.21% 1.96B
-0.23%-8.32%+19.30%+124.23% 1.39B
+0.99%+7.99%-15.10%+0.88% 1.22B
+1.68%+1.99%-12.01%-44.23% 993M
Average +0.47%-1.15%+3.62%+20.99% 6.23B
Weighted average by Cap. +0.67%-5.86%-18.25%-8.92%

Financials

2026 *2027 *
Net sales 1.55B 1.79B 1.45B 1.32B 2.5B 171B 2.54B 17B 6.67B 85.48B 6.73B 6.58B 285B 1.65B 1.9B 1.54B 1.41B 2.65B 181B 2.69B 18.06B 7.08B 90.79B 7.15B 6.99B 302B
Net income 171M 198M 160M 146M 275M 18.85B 280M 1.88B 736M 9.43B 742M 726M 31.41B 190M 219M 177M 162M 305M 20.88B 310M 2.08B 815M 10.45B 822M 804M 34.79B
Net Debt 127M 146M 118M 108M 204M 13.96B 207M 1.39B 545M 6.99B 550M 538M 23.27B 75.16M 86.82M 70.25M 64.21M 121M 8.28B 123M 824M 323M 4.14B 326M 319M 13.8B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
-
Date Price Change
10/08/26 333.00 -3.20%
07/08/26 €344.00 +0.44%
06/08/26 €342.50 +1.48%
05/08/26 €337.50 -0.15%
04/08/26 €338.00 +0.30%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
345.00EUR
Average target price
411.88EUR
Spread / Average Target
+19.38%

Quarterly revenue - Rate of surprise